PMID- 34295853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2319-9644 (Print)
IS  - 2279-042X (Electronic)
IS  - 2279-042X (Linking)
VI  - 10
IP  - 1
DP  - 2021 Jan-Mar
TI  - Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid 
      Tumors.
PG  - 50-56
LID - 10.4103/jrpp.JRPP_21_3 [doi]
AB  - OBJECTIVE: Type 2 diabetes mellitus (T2DM) affects 10% of Americans and is 
      associated with an increased incidence of cancer. Statins are first-line 
      cholesterol-lowering medications in the treatment of hyperlipidemia. Several 
      studies have demonstrated a relationship between statin use and reduced cancer 
      incidence. We examined the cancer benefits of statin subtypes, with specific 
      attention to disease-free survival (DFS) and overall survival (OS). METHODS: This 
      retrospective review included adults with T2DM diagnosed with solid tumors at 
      Roswell Park Cancer Institute in Buffalo, NY, USA (2003-2010). Individuals with 
      gestational diabetes, incomplete records, or diagnosed with rare solid tumors 
      were excluded. Follow-up began at the date of diagnosis and ended with the first 
      confirmed recurrence, death, or loss of contact. Demographics were assessed by 
      Chi-square, Kaplan-Meier survival analyses, and Cox proportional hazards 
      regression. FINDINGS: Overall, 1102 patients met inclusion criteria, 52.1% of the 
      study participants were female, and 578 participants (52.5%) died during the 
      follow-up period which ranged from 0 to 156 months. Hydrophilic statin use was 
      associated with improved DFS at 5-year follow-up (41.0% vs. 36.9%, P = 0.0077) 
      compared to lipophilic statin use. Multivariate regression revealed that 
      hydrophilic statins were associated with improved DFS (hazard ratio [HR]: 0.706, 
      95% confidence interval [CI]: 0.526-0.947) and OS (HR: 0.685, 95% CI: 
      0.503-0.934). Pravastatin was associated with improved OS (HR: 0.674, 95% CI: 
      0.471-0.964). CONCLUSION: In patients with T2DM and cancer, hydrophilic statins, 
      and pravastatin in particular, are associated with improved DFS as well as OS. 
      Further research examining the cancer-specific effects of hydrophilic and 
      lipophilic statins is needed to better understand their beneficial effects.
CI  - Copyright: (c) 2021 Journal of Research in Pharmacy Practice.
FAU - Ceacareanu, Alice C
AU  - Ceacareanu AC
AD  - Translational Biomedical Research Management Graduate Program, Hartwick College, 
      Oneonta, New York, USA.
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 
      State University of New York at Buffalo, Buffalo, New York, USA.
AD  - Pharmacy Services, Roswell Park Cancer Institute, Buffalo, New York, USA.
AD  - Clinical Services, ROAKETIN Inc., Oneonta, New York, USA.
FAU - Jolly, Shanria D
AU  - Jolly SD
AD  - Translational Biomedical Research Management Graduate Program, Hartwick College, 
      Oneonta, New York, USA.
FAU - Nimako, George K
AU  - Nimako GK
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 
      State University of New York at Buffalo, Buffalo, New York, USA.
AD  - Pharmacy Services, Roswell Park Cancer Institute, Buffalo, New York, USA.
FAU - Wintrob, Zachary A P
AU  - Wintrob ZAP
AD  - Translational Biomedical Research Management Graduate Program, Hartwick College, 
      Oneonta, New York, USA.
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 
      State University of New York at Buffalo, Buffalo, New York, USA.
AD  - Pharmacy Services, Roswell Park Cancer Institute, Buffalo, New York, USA.
AD  - Clinical Services, ROAKETIN Inc., Oneonta, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20210513
PL  - India
TA  - J Res Pharm Pract
JT  - Journal of research in pharmacy practice
JID - 101614023
PMC - PMC8259595
OTO - NOTNLM
OT  - Cancer mortality
OT  - cancer recurrence
OT  - diabetes mellitus
OT  - hydrophilic statins
OT  - lipophilic statins
OT  - pravastatin
COIS- Zachary A. P. Wintrob is affiliated with ROAKETIN Inc. and Alice C. Ceacareanu 
      owns stock in ROAKETIN Inc. None of the authors report any relevant personal or 
      financial conflicts of interest to disclose.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2021/05/13
CRDT- 2021/07/23 06:51
PHST- 2020/10/07 00:00 [received]
PHST- 2021/01/04 00:00 [accepted]
PHST- 2021/07/23 06:51 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2021/05/13 00:00 [pmc-release]
AID - JRPP-10-50 [pii]
AID - 10.4103/jrpp.JRPP_21_3 [doi]
PST - epublish
SO  - J Res Pharm Pract. 2021 May 13;10(1):50-56. doi: 10.4103/jrpp.JRPP_21_3. 
      eCollection 2021 Jan-Mar.